Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

New deal strategy gives AbCellera more upside without straying from its roots

Tachyon, EQRx deals give AbCellera options to invest in development, gaining more royalties, ownership of assets

By Virginia Li, Associate Editor
August 4, 2021 11:42 PM UTC

Via its deals with EQRx and Tachyon, AbCellera has unveiled a new partnership strategy that could provide the biotech with more upside without straying from its discovery-focused business model.

On Wednesday, AbCellera Biologics Inc. (NASDAQ:ABCL) partnered with EQRx Inc. to discover and develop multiple undisclosed mAbs spanning therapeutic areas, with an initial focus on targets in oncology and immunology. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abcellera Biologics Inc.

Eqrx Inc.